Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmaron Beijing CoPHBBF 90 Debt-to-EBITDA is 3.82 as of Mar. 2026, which is 79% above its 10-year median of 2.13. GuruFocus rates PHBBF with a GF Score™ of 90/100 and a GF Value™ of $1.43. The stock has 9 warning signs investors should review. Among 298 Biotechnology companies, Pharmaron Beijing Co ranks worse than 72.48% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Pharmaron Beijing Co's Debt-to-EBITDA or its related term are showing as below:
PHBBF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.61 Med: 2.13 Max: 3.29
Current: 3.28
During the past 12 years, the highest Debt-to-EBITDA Ratio of Pharmaron Beijing Co was 3.29. The lowest was 0.61. And the median was 2.13.
PHBBF's Debt-to-EBITDA is ranked worse than 72.48% of 298
companies
in the Biotechnology industry
Industry Median: 1.15
vs PHBBF: 3.28
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Pharmaron Beijing Co Debt-to-EBITDA Related Terms
Pharmaron Beijing Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Pharmaron Beijing Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHBBF vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Pharmaron Beijing Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmaron Beijing Co Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Pharmaron Beijing Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Pharmaron Beijing Co (PHBBF) has a Debt-to-EBITDA of 3.82 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Pharmaron Beijing Co. This is 79% above median its historical median of 2.13. Over the past decade, Pharmaron Beijing Co's Debt-to-EBITDA has ranged from 0.61 to 3.29. According to the industry distribution chart, Pharmaron Beijing Co ranks #216 out of 298 companies in the Biotechnology industry, placing it in the top 72.5%.
Is Pharmaron Beijing Co's Debt-to-EBITDA too high?
Pharmaron Beijing Co's current Debt-to-EBITDA of 3.82 is 79% above median its 10-year median of 2.13. Over the past 10 years, this metric has ranged from a low of 0.61 to a high of 3.29. The Biotechnology industry median Debt-to-EBITDA is 1.15. Pharmaron Beijing Co's value of 3.82 is 232.2% above this industry median. Based on the distribution chart, Pharmaron Beijing Co ranks #216 out of 298 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pharmaron Beijing Co has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmaron Beijing Co ranks #216 out of 298 companies for Debt-to-EBITDA. This places Pharmaron Beijing Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.15. Pharmaron Beijing Co's value of 3.82 is 232.2% above this benchmark. Historically, Pharmaron Beijing Co's own Debt-to-EBITDA has ranged from 0.61 to 3.29 over the past decade. While the company's 10-year median is 2.13 vs. the industry median of 1.15, Pharmaron Beijing Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.15, based on 298 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmaron Beijing Co's current Debt-to-EBITDA of 3.82 is 232.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Pharmaron Beijing Co. For the Biotechnology industry, the median Debt-to-EBITDA is 1.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmaron Beijing Co's current Debt-to-EBITDA is 3.82, which is 79% above median its own 10-year median of 2.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Pharmaron Beijing Co (PHBBF) has a current Debt-to-EBITDA of 3.82. The stock's GF Value™ is $1.43, compared to a current price of $1.93 — trading 35% above its estimated fair value. The current Debt-to-EBITDA is 3.82, which is 79% above median its 10-year median of 2.13 and 232.2% above the Biotechnology industry median of 1.15. Pharmaron Beijing Co's overall GF Score™ is 90/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Pharmaron Beijing Co (PHBBF), the current Debt-to-EBITDA is 3.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaron Beijing Co (PHBBF) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued.
The current stock price of $1.93 is trading 35% above its estimated GF Value™ of $1.43.
Key valuation signals for PHBBF:
Debt-to-EBITDA: 3.82 (79% above median its 10-year median of 2.13)
GF Value™: $1.43 vs. price of $1.93 (35% above fair value)
Industry Position: 232.2% above the Biotechnology median (#216 of 298)
No single metric tells the full story. See the PHBBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
90GF Score
Get the complete analysis for PHBBF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHBBF has been successfully added to your 
